NRx Pharmaceuticals (NRXP)
Develops NMDA-pathway CNS therapies alongside a majority-owned interventional-psychiatry clinic network.
Something off on this page? Send us feedback.
Develops NRX-100 and NRX-101, two CNS drug candidates targeting the NMDA pathway. Through its majority-owned HOPE Therapeutics network, it also provides interventional psychiatric care integrating neuroplastic drugs, TMS, digital therapeutics, and hyperbaric therapy.
Develops the NRX-100 and NRX-101 CNS drug candidates, based on the NMDA pathway. NRX-100 is a preservative-free intravenous ketamine formulation, and NRX-101 combines oral D-cycloserine with lurasidone. Both programs remain in development, rather than approved products.
HOPE Therapeutics supplies a care-delivery arm alongside NeuroRx's pharmaceutical-development work. The majority-owned network delivers interventional psychiatric care through neuroplastic drugs, TMS, digital therapeutics, and hyperbaric therapy, with clinics in Florida. The listed public issuer arose from a NeuroRx/SPAC merger.
Drug candidates require regulatory progress, while the newer clinic network depends on early care-delivery execution.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $26.7M · Total debt $1.2M · Total assets $34.2M · Shareholders' equity −$170.0K
- Revenue
- $1.1M
- Operating income
- −$6.5M
- Net income
- −$16.5M
No dividends on record.
| Institutions | 67.33% | 11.64M shares | |
|---|---|---|---|
| 52 holders · as of Jun 30, 2026 | |||
| Insiders | 0.49% | 84.6K shares | |
| 1 holder · as of Dec 18, 2024 | |||
| Strategic holders | 0.38% | 65.6K shares | |
| 1 holder · as of May 26, 2021 | |||
| Other | 31.80% | 5.50M shares | |
| remainder | |||
17.29M company shares as of Sep 13, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (43.30M in the company's Sep 23, 2026 report, 17.29M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
B Group, Inc.Institution | 23.67% | 4.09M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 9.36% | 1.62M | as of Jun 30, 2026 |
Anson Funds Management LPInstitution | 9.28% | 1.60M | filed Aug 14, 2025 |
Ameriprise Financial IncInstitution | 5.37% | 928,728 | as of Jun 30, 2026 |
Balyasny Asset Management L.P.Institution | 5.17% | 893,864 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Johnson & Johnson
Esketamine treatment for treatment-resistant and acute-suicidality depression
- Neuronetics
TMS systems and Greenbrook clinics for depression care
- AbbVie
Oral cariprazine therapy for bipolar depression and adjunctive MDD
- Axsome Therapeutics
Rapid-acting oral NMDA therapy for major depressive disorder
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NRx Pharmaceuticals | $3.14 | −5.57% | $57.4M | — | — | 16.9 | — |
| Johnson & Johnson | $268.29 | −0.33% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Neuronetics | $2.88 | −1.20% | $202.5M | — | — | 1.3 | +9.1% |
| AbbVie | $264.72 | −0.18% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Axsome Therapeutics | $192.26 | −5.34% | $10.45B | — | 1,147.1 | 13.5 | +44.2% |
| Median | 53.0 | 22.6 | 7.0 | +9.6% |